DMAX
DMAX, licence 80050185: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Commonhealth Canada Inc.
- NPN or DIN-HM
- 80050185
- Status
- Active licence
- Licence date
- 14 April 2014
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Medicago sativa L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Frangula purshiana Cooper: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes ainsi qu'une mention déconseillant l'usage prolongé.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Plantago ovata Source : Enveloppe | 50.0 mg | Not calculated |
| Medicago sativa Source : Sommité | 92.0 mg | Not calculated |
| Frangula purshiana Source : Écorce âgée | 1.0 mg | Not calculated |
| Frangula alnus Source : Écorce (tige) | 0.5 mg | Not calculated |
Non-medicinal ingredients
Dioxyde de silicium, Stéarate de magnésium, Cellulose microcristalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19.0 Année(s) | 3.0 Comprimé | 1.0 Jour(s) |
Uses authorised in Canada
Lactobacillus acidophilus provides live microorganisms that temporarily modify gut flora. Source of probiotics.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
Hypersensitivity, such as allergy, has been known to occur following inhaled and/or ingested psyllium; in which case discontinue use. May cause temporary gas and/or bloating. Some people may experience headaches. May cause diarrhea, in which case, discontinue use.
- Contre-indications
Do not use if you are pregnant, breastfeeding, trying to conceive, or have a history of systemic lupus erythematosus. Do not use if you are experience a sudden change in bowel habits that has persisted for more than 2 weeks, undiagnosed rectal bleeding, or failure to defaecate following the use of another laxative product. Do not use if you have acute stomach irritation, inflammation, stomach/duodenal ulcers, or diabetes in which blood sugar is difficult to regulate. Do not use if you have difficulty swallowing. If you have an immune-compromised condition (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment), do not use this product. Do not use if you have abnormal constrictions of the gastrointestinal tract, potential or existing intestinal blockage, atonic bowel, appendicitis, inflammatory colon disease such as Crohn's disease or ulcerative colitis, abdominal pain of unknown origin, severe dehydration with depleted electrolytes or diarrhoea.
- Précautions et mises en garde
Consult a health care practitioner prior to use if you are taking blood thinners, medications which inhibit peristaltic movement (e.g. opiods, loperamide), birth control medication, thiazide diuretics, corticosteroids, licorice root, other medications or health products that may aggravate electrolyte imbalance, cardiac medications such as cardiac glycosides or antiarrhythmic medications, or if you are are undergoing hormone replacement therapy (HRT). Consult a health care practitioner immediately if you experience chest pain, vomiting, or difficulty in swallowing or breathing after taking this product. Consult a health care practitioner prior to use if you have symptoms such as abdominal pain, nausea, vomiting, bloody diarrhea, or fever (as these could be signs of abnormal constrictions of the gastrointestinal tract, diseases of the oesophagus and/or the superior opening of the stomach (cardia), potential or existing intestinal blockage, paralysis of the intestine, megacolon, faecal impaction, inflamed bowel, or appendicitis. If symptoms of digestive upset (e.g. diarrhoea) occur, worsen, or persist beyond 3 days, discontinue use and consult a health care practitioner. Consult a health care practitioner prior to use if you have hemorrhoids, blood pressure problems, or a kidney disorder. Reduce dose or discontinue use if you experience abdominal pain, cramps, spasms, and/or diarrhoea. Consumption of goldenseal with alcohol, other medications and/or natural health products with sedative properties is not recommended.
Source
Official Health Canada record, licence 80050185
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.